Sign In
Buy INBX
$95.22
+1.59 (+1.70%)
At Close: Jun 03, 2026
Inhibrx, Inc. (INBX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
04:48pm, Friday, 05'th Nov 2021
Inhibrx, Inc. (INBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences
05:51pm, Monday, 01'st Nov 2021
SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the
Here's Why Inhibrx Stock Is on the Move Today
12:11pm, Tuesday, 12'th Oct 2021
The first clinical trial results for a candidate for the treatment of alpha-1 antitrypsin deficiency look highly encouraging.
Inhibrx Announces Participation in Upcoming Investor Conference
04:30pm, Monday, 13'th Sep 2021
SAN DIEGO, Sept. 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announce
Inhibrx Reports Second Quarter 2021 Financial Results
04:38pm, Monday, 09'th Aug 2021
SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the second quarter of 202
SAN DIEGO, June 21, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Ph
Week 24 MDA Breakout Stocks - June 2021: Short-Term Picks To Give You An Edge
09:22am, Sunday, 13'th Jun 2021
Two new sample breakout stocks for Week 24 with better than 10% short-term upside potential. This past week the peak gains were in LIZI +28.9% and LQDT +10.3% with all 4 picks giving back gains to the
Inhibrx Announces Participation in Upcoming Investor Conferences
04:05pm, Monday, 17'th May 2021
SAN DIEGO, May 17, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced
Inhibrx's INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study
11:53am, Friday, 12'th Mar 2021
Inhibrx Inc (NASDAQ: INBX) has announced results from the dose escalation of the Phase 1 study evaluating INBRX-105 in locally advanced or metastatic solid tumors. INBRX-105 is a precisely enginee
SAN DIEGO, March 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and
U.S. IPO Week Ahead: The IPO Market Braces For A September SNOWstorm In A 12-IPO Week
11:07am, Sunday, 13'th Sep 2020
The post-Labor Day IPO frenzy is here as 12 IPOs plan to raise $6.8 billion in the coming week, led by cloud data unicorn Snowflake.
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
10:49am, Friday, 11'th Sep 2020
Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71.
U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week
06:48am, Sunday, 23'rd Aug 2020
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. The week's eight SPAC IPOs raised $3.3 billion.
U.S. IPO Week Ahead: The IPO Market's Summer Slowdown Approaches In A 3-IPO Week
03:41pm, Saturday, 15'th Aug 2020
Two biotechs, a medical imaging company, and two SPACs are scheduled to go public in the week ahead. Another biotech, Kymera Therapeutics, is eligible to launch.
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
08:30am, Saturday, 15'th Aug 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
